Reports Q4 revenue $79M, consensus $79.01M. “We reached a significant inflection point in 2024, achieving full-year profitability ahead of expectations while delivering our fifth consecutive year of revenue growth exceeding 30%,” said David Moatazedi, President and Chief Executive Officer of Evolus (EOLS). “Jeuveau continues to outperform the market, driven by strong consumer loyalty and increasing adoption, and we are now entering 2025 focused on transforming Evolus into a multi-product, performance beauty company with the imminent launch of Evolysse. The combination of Jeuveau and Evolysse brings together the fastest growing neurotoxin in the U.S. with the first innovation in HA technology in a decade.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EOLS:
- EOLS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Evolus: Strategic Developments and FDA Approvals Drive Buy Rating with Promising Growth Projections
- Evolus Gains ‘Buy’ Rating: FDA Approval and Unique Technology Drive Growth Potential
- Evolus Gains Buy Rating on Early FDA Approval and Strategic Market Positioning
- Evolus’s Strategic Advancements and Early FDA Approval Boost Growth Potential